𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Strategy for design of clinical trials of chemopreventive agents

✍ Scribed by Stimson P. Schantz; Waun Ki Hong; Charles W. Boone; Gary J. Kelioff

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
108 KB
Volume
53
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Criteria for implementation of large and
Criteria for implementation of large and multiagent clinical chemoprevention trials
✍ Frank L. Meyskens Jr. πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 79 KB

If one were to wait for the perfect set of experimental results before launching a multi-agent chemoprevention or large risk reduction study, the trial would never be launched. On the other hand, non-scientific considerations have led to the premature launching of at least three prominent studies (C

Clinical research priorities in Renal ce
Clinical research priorities in Renal cell carcinoma : Renal cell carcinoma chemoprevention strategies including target populations, proposed agents, and clinical trial designsβ€”Workgroup No. 6
✍ Kamal A. Hanash; Joseph W. Aquilina; David M. Barrett; Michael L. Blute; Abraham πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 50 KB πŸ‘ 2 views

C hemoprevention refers to the prevention of cancer or reduction of risk in susceptible individuals by the administration of natural or synthetic drugs with minimal toxicity to suppress, delay, or reverse carcinogenesis. 1 Chemoprevention is most effective in the early stages of cancer formation whe

Guidance for development of chemoprevent
Guidance for development of chemopreventive agents
✍ Gary J. Kelloff; John R. Johnson; James A. Crowell; Charles W. Boone; Joseph J. πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 381 KB

Approaches to the development and marketing approval of cancer chemopreventive agents have been described by a Working Group from the National Cancer Institute and the Food and Drug Administration in a recent publication [l]. The approaches described do not constitute regulatory requirements, but ra

Colon cancer chemoprevention: Clinical d
Colon cancer chemoprevention: Clinical development of aspirin as a chemopreventive agent
✍ Krishnan, Koyamangalath; Ruffin, Mack T.; Brenner, Dean E. πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 81 KB πŸ‘ 2 views

We have studied aspirin as a potential chemopreventive for colorectal cancer, completing Phase I studies on aspirin pharmacology and potential biomarker assays (prostaglandins, PGE 2 and PGF 2␣ and cyclooxygenase modulation) in normal human subjects. These studies have determined the optimal dose of